In June 2022, Shionogi and GARDP signed the first-ever voluntary license agreement for an antibiotic between a pharmaceutical company and a non-profit organization*. STAT news announced, “In a first-of-its-kind deal, major drugmaker licenses antibiotic production for low-income countries.” More colourfully, Fierce Pharma noted, “Shionogi quests to slay antibiotic resistance with cefiderocol licensing and collaboration troika.” Members of the project team received excited congratulations from fellow global health experts. But now, more than two years down the line, what is the status of this project? How much closer are the project partners to making the antibiotic cefiderocol accessible in the GARDP territory? What challenges have the project partners encountered, and what can the broader global health community learn from them? This webinar will ask project partners to respond to such questions and to evaluate the implications for antibiotic access more generally. Q&A to follow.

*apart from TB medicines

Speakers:

• Monika Schneider, Shionogi Inc.
• Rahul Dwivedi, GARDP
• Melynda Watkins, CHAI
• Manish Dhanuka, Orchid Pharma

Moderated by Peter Beyer, Deputy Executive Director, GARDP

This live webinar including an interactive Q&A session will be broadcast on 28 March 2025 at 15:00-16:15 CET.

REGISTER NOW